Skip to main content
. Author manuscript; available in PMC: 2018 Jun 1.
Published in final edited form as: Neurobiol Dis. 2017 Aug 18;108:73–82. doi: 10.1016/j.nbd.2017.08.006

Fig. 4.

Fig. 4

IMPs treatment reduces chondroitin sulfate proteoglycan (CSPG) accumulation. (A) Representative images of 16 μm thick mid-sagittal sections of PBS or IMPs treated animals 13 weeks post SCI stained with CS-56 and GFAP. Scale bar = 250 μm (B) Quantifications of CS-56 intensities in the GFAP− lesion core (Lesion Core) and in the 250 μm wide GFAP+ glial border area that immediately surrounds the lesion (Lesion Rim) (n = 3 mice per group, **p < 0.01, ***p < 0.001, Student’s t-test). (C) Western blot analysis of the protein samples obtained from the 1 mm lesion-containing segments of spinal cords treated with PBS or IMPs at 41 weeks post SCI (n = 3–5 per group) show reduced levels of tenascin R after IMPs treatment. (D, E) IMPs treatment did not alter levels of either tenascin C or laminin 41 weeks post SCI (n = 3–5 per group) (F) Quantification shows that IMPs treatment reduced levels of tenascin R but not tenascin C or laminin 41 weeks post SCI (n = 3 mice per group).